Repro Med Systems/$KRMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Repro Med Systems
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
Ticker
$KRMD
Sector
Primary listing
Employees
73
Headquarters
Website
KRMD Metrics
BasicAdvanced
$206m
-
-$0.05
0.42
-
Price and volume
Market cap
$206m
Beta
0.42
52-week high
$6.61
52-week low
$2.91
Average daily volume
142k
Financial strength
Current ratio
2.326
Quick ratio
1.704
Long term debt to equity
16.651
Total debt to equity
19.889
Profitability
EBITDA (TTM)
-1.92
Gross margin (TTM)
61.93%
Net profit margin (TTM)
-5.27%
Operating margin (TTM)
-5.99%
Effective tax rate (TTM)
-0.97%
Revenue per employee (TTM)
$590,000
Management effectiveness
Return on assets (TTM)
-5.81%
Return on equity (TTM)
-13.70%
Valuation
Price to revenue (TTM)
4.804
Price to book
12.24
Price to tangible book (TTM)
12.78
Price to free cash flow (TTM)
1,807.568
Free cash flow yield (TTM)
0.06%
Free cash flow per share (TTM)
0.002
Growth
Revenue change (TTM)
23.30%
Earnings per share change (TTM)
-54.87%
3-year revenue growth (CAGR)
14.20%
3-year earnings per share growth (CAGR)
-34.89%
What the Analysts think about KRMD
Analyst ratings (Buy, Hold, Sell) for Repro Med Systems stock.
KRMD Financial Performance
Revenues and expenses
KRMD Earnings Performance
Company profitability
KRMD News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs